摘要
基于西医肠肾轴概念从中医脏腑理论谈孙伟教授治疗慢性肾脏病经验,孙伟教授早在肠肾轴提出前已应用"补益肺肾,活血清利法"论治慢性肾脏病,为临床治疗慢性肾脏病指出了新方向。
Based on the theory of intestinal and renal axis in Western medicine, professor Sun Wei′ s experience of treating chronic kidney disease(CKD) was discussed from TCM viscera theory, professor Sun Wei has applied the method of "tonifying lung and kidney, promoting blood circulation and clearing" to CKD before the theory of gut-kidney axis was raised, therefore to point out new directions for clinical treatment for CKD.
引文
[1]Stevens PE,Levin A.Kidney disease:improving global outcomes chronic kidney disease guideline development work group members evaluation and management of chronic kidney disease:synopsis of the kidney disease:improving global outcomes 2012 clinical practice guideline[J].Ann Intern Med,2013,158(11):825-830.
[2]Glenwright AJ,Pothula KR,Bhamidimarri SP,et al.Structural basis for nutrient acquisition by dominant members of the human gut microbiota[J].Nature,2017,541(7637):407-415.
[3]Emy D,Prinz M.Microbiology:gut microbes augment neurodegeneration[J].Nature,2017,544(7650):304.
[4]薛畅,李强.肠道菌群与肥胖关系研究进展[J].中国实用内科杂志,2017,37(1):76-79.
[5]Viennois E,Merlin D,Gewirtz AT,et al.Dietary emulsifier-induced Low-grade inflammation promotes colon carcinogenesis[J].Cancer Res,2017,77(1):27.
[6]黄源春,谭学瑞.肠道菌群与心血管疾病相关:现状与未来[J].世界华人消化杂志,2017,25(1):31-42.
[7]袁伟杰,王玲.肠道微生态与肾脏疾病[J].肾脏病与透析肾移植杂志,2017,26(2):153-154.
[8]Meijers BK,Evenepoel P.The gut-kidney axis:indoxyl sulfate,p-cresyl sulfate and CKD progression[J].Nephrol Dial Transplant,2011,26(3):759-761.
[9]Wang IK,Wu YY,Yang YF,et al.The effect of probiotics on serum levels of cytokine and endotoxin in peritoneal dialysis patients:a randomised,doubleblind,placebo-controlled trial[J].Benef Microbes,2015,6(4):423-430.
[10]Taki K,Takayama F,Niwa T.Beneficial effects of Bifidobacteria in a gastroresistant seamless capsule on hyperhomocysteinemia in hemodialysis patients[J].J Ren Nutr,2005,15(1):77-80.
[11]黄馨,白瑜,于李汀,等.肾康栓对于慢性肾脏病的治疗效果及临床应用[J].医学与哲学,2017,38(16):35-37.
[12]Sartor RB.Microbial influences in inflammatory bowel diseases[J].Gastroenterology,2008,134(2):577-594.
[13]Vaziri ND,Wong J,Pahl M,et al.Chronic kidney disease alters intestinal microbial flora[J].Kidney Int,2013,83(2):308-315.
[14]Wang F,Zhang p,Jiang H,et al.Gut bacterial translocation contributes to microinflammation in experimental uremia[J].Dig Dis Sci,2012,57(11):2856-2862.
[15]邹川,吴禹池,罗丽,等.中药大黄复方灌肠对慢性肾脏病5期(非透析)肠道菌群和肠道屏障功能影响的临床研究[J].辽宁中医杂志,2012,39(7):1309-1311.
[16]Evenepoel P,Meijers BK,Bammens BR,et al.Uremic toxins originating from colonic microbial metabolism[J].Kidney Int Suppl,2009,76(114):12-19.
[17]Tang WH,Wang Z,Kennedy DJ,et al.Gut microbiotal dependent trimethylamine N-oxide(TMAO)pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease[J].Circ Res,2015,116(3):448-455.
[18]Lekawanvijit S.Role of gut-derived protein-hound uremic toxins in cardiorenal syndrome and potential treatment modalities[J].Circ J,2015,79(10):2088-2097.
[19]Pahl MV,Vaziri ND.The chronic kidney disease-colonic axis[J].Semin Dia1,2015,28(5):459-463.
[20]姜东京,张丽,曹雨诞,等.肠道菌群在中药研究中的应用[J].中国中药杂志,2016,41(17):3218-3225.
[21]张英谦,刘建华,李细贵,等.大黄对脓毒症幼猪肠屏障保护作用及机制研究[J].中华中医药杂志,2007,22(12):843-847.
[22]李佳.从肺论治肾脏疾病浅识[J].实用中医内科杂志,2010,24(12):51-52.
[23]王虹,张东友.影像医学研究中医“肺与大肠表里关系”的思路浅析[J].中国中西医结合影像学杂志,2012,10(1):71-73.
[24]韩国栋.“肺与大肠相表里”理论中西医结合研究进展[J].天津中医,1995,12(4):45-48.
[25]高坤,孙伟,周栋,等.慢性肾脏病中医证型分布及演变规律研究[J].江苏中医药,2008,40(6):33-35.
[26]焦志娜,张昱.黄芪治疗肾脏病机理研究进展[J].中国中医药现代远程教育,2012,10(22):155-157.
[27]孙政华,邵晶,郭玫.党参化学成分及药理作用研究进展[J].安徽农业科学,2015,43(33):174-176.
[28]鄢伟伦,王帅帅,任霞.白术对小鼠肠道菌群调节作用的实验研究[J].山东中医杂志,2011,30(6):417-419.
[29]宋厚盼,谢梦洲,胡志希,等.白术、黄芪、党参促进IEC-6细胞损伤后快速修复[J].中成药,2015,37(6):1170-1175.
[30]梁金花,郑科文,金大伟.黄芪多糖对溃疡性结肠炎大鼠肠道菌群调节作用的研究[J].中国中医药科技,2012,19(4):331-332.
[31]杨敏,林焕冰,张金桃,等.黄芪多糖对炎症性肠病模型大鼠NFATC4表达的影响[J].中国循证儿科杂志,2012,7(5):389-392.
[32]刘艳艳,张凯,关家伟,等.人参皂苷对BALB/c小鼠肠道菌群的影响[J].现代生物医学进展,2015,15(6):1041-1045.
[33]郑秀丽,杨宇,郑旭锐,等.从肺肠菌群变化的相关性探讨“肺与大肠相表里”[J].中华中医药杂志,2013,28(8):2294-2296.